Back to news

MediWound to Host Virtual KOL Event on EscharEx® Phase III VALUE Study and Commercial Opportunity on December 2, 2026

Globe Newswire•16/11/2026•08:00 ET
1

Key Highlights

  • ➤December 2, 2026 KOL event will address EscharEx Phase III VALUE study
  • ➤EscharEx targets debridement and wound closure in chronic wounds
  • ➤$1.05 billion estimated U.S. annual peak sales potential
  • ➤Phase III VALUE trial underway in venous leg ulcers
  • ➤Future studies planned in diabetic foot and pressure ulcers

MediWound to Host Virtual KOL Event on EscharEx(®) Phase III VALUE Study and Commercial Opportunity on December 2, 2026

Leading wound care experts to discuss Phase II clinical evidence, the pivotal Phase III VALUE study, and the estimated $1.05 billion U.S. annual peak sales potential

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in